Simplex Trading
BTAI icon

Simplex Trading’s BioXcel Therapeutics BTAI Stock Holding History

Simplex Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-195
Closed -$1.63K – 8557
2024
Q3 		$1K Sell
195
-1,823
-90% -$24.5K ﹤0.01% 8141
2024
Q2 		$41K Buy
2,018
+1,123
+125% +$37.6K ﹤0.01% 6266
2024
Q1 		$40K Buy
+895
New +$42.7K ﹤0.01% 6453
2023
Q4 		– Sell
-505
Closed -$28.1K – 8822
2023
Q3 		$20K Buy
+505
New +$51K ﹤0.01% 6607
2023
Q2 		– Sell
-455
Closed -$152K – 9003
2023
Q1 		$135K Buy
455
+297
+188% +$127K ﹤0.01% 4801
2022
Q4 		$54K Buy
+158
New +$38.2K ﹤0.01% 5777
2022
Q2 		– Sell
-1,100
Closed -$231K – 9993
2022
Q1 		$367K Buy
1,100
+979
+809% +$284K ﹤0.01% 4267
2021
Q4 		$39K Buy
121
+52
+75% +$22.3K ﹤0.01% 7559
2021
Q3 		$31K Buy
69
+6
+10% +$2.64K ﹤0.01% 8054
2021
Q2 		$29K Sell
63
-63
-50% -$34.3K ﹤0.01% 8255
2021
Q1 		$87K Sell
126
-78
-38% -$62.7K ﹤0.01% 5929
2020
Q4 		$0 Buy
+204
New +$159K ﹤0.01% 8350
2020
Q3 		– Sell
-1,961
Closed -$1.47M – 7800
2020
Q2 		$1.66M Sell
1,961
-698
-26% -$455K ﹤0.01% 1658
2020
Q1 		$950K Buy
+2,659
New +$956K ﹤0.01% 1936

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Simplex Trading's BTAI Position: Q4 2024 in Review

Simplex Trading sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 195 shares — an estimated $1.63K sold.

Simplex Trading first reported a position in BTAI in Q1 2020 and held it in 14 quarters. The position peaked at $1.66M in Q2 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

  • Simplex Trading reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 195 BioXcel Therapeutics shares in Q4 2024, an estimated $1.63K.
  • Simplex Trading first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 14 quarters.
  • Simplex Trading's BioXcel Therapeutics position peaked at $1.66M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.